WebDec 15, 2024 · NEW YORK, Dec. 15, 2024 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments for depression and other mental health ... WebMay 6, 2024 · Gilgamesh Pharmaceuticals, a biotechnology company that uses psychedelic-related drugs to treat neuropsychiatric disorders, reported Thursday it has raised $27 million in a Series A funding round ...
Gilgamesh Pharmaceuticals LinkedIn
WebMay 16, 2024 · Compass Pathways (stock ticker NASDAQ: CMPS) has launched clinical trials in 20 countries with a focus on treatment-resistant depression. In addition, Johnson … WebGilgamesh is a serious mental health science focused, preclinical biotechnology company. We have a disciplined focus on developing innovative new chemical entities (NCE’s) … tall with small frame
Gilgamesh Pharmaceuticals Closes On $27 Million …
WebDec 15, 2024 · NEW YORK, Dec. 15, 2024 /PRNewswire/ -- Gilgamesh Pharmaceuticals, a biotechnology company developing a portfolio of rapid-acting and durable treatments … WebApr 9, 2024 · Based in Austin, TX, Heading Health provides a number of treatment options for mental health challenges, including ketamine for treatment-resistant depression. They recently announced that they have participated in a Series A Preferred Stock Financing with Entheon Biomedical Corp. (CSE: ENBI), investing $200,000 USD for a 5% stake in … WebOct 14, 2024 · Funding. Gilgamesh Pharmaceuticals has raised a total of $68.6M in funding over 7 rounds. Their latest funding was raised on Dec 15, 2024 from a Series B round. Gilgamesh Pharmaceuticals is funded by 18 investors. Prime Movers Lab and JLS Fund are the most recent investors. two tone custom hat